Citation: Radiation Oncology. 13(1):26, 2018 Feb 13.Journal: Radiation oncology (London, England).Published: ; 2018ISSN: 1748-717X.Full author list: Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J.UI/PMID: 29439707.Subject(s): Adult | Aged | Aged, 80 and over | Female | Follow-Up Studies | Humans | International Agencies | *Liver Neoplasms/sc [Secondary] | *Liver Neoplasms/su [Surgery] | Male | Middle Aged | Prognosis | *Radiosurgery | Radiotherapy Dosage | *Registries/sn [Statistics & Numerical Data] | Retrospective Studies | Survival RateInstitution(s): Washington Cancer InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1186/s13014-018-0969-2 (Click here)ORCID: Mahadevan, Anand http://orcid.org/0000-0003-3555-4217 (Click here)Abbreviated citation: Radiat. oncol.. 13(1):26, 2018 Feb 13.Abstract: BACKGROUND: Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry.Abstract: METHODS: Patients with liver metastases treated with SBRT were identified in the RSSearch Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED<sub>10</sub>. Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test.Abstract: RESULTS: The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm<sup>3</sup> (1.6-877 cm<sup>3</sup>), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p<0.0001). Smaller tumor volumes (<40 cm<sup>3</sup>) correlated with improved OS (25 months vs 15 months p=0.0014). BED<sub>10</sub>>=100 Gy was also associated with improved OS (27 months vs 15 months p<0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED<sub>10</sub>>=100 Gy (77.2% vs 59.6%) and the median LC was better for tumors <40 cm<sup>3</sup> (52 vs 39 months). There was no difference in LC based on histology of the primary tumor.Abstract: CONCLUSIONS: In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted.Abstract: TRIAL REGISTRATION: Clinicaltrials.gov: NCT01885299 .